Analytical Data
-
Gene name
HLA-DRB1
- Application
-
Alternative Names
MHC class II antigen DRB1*1
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04229
-
Expression Region
30-227aa
-
Molecular Weight
42.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-DRB1, a crucial gene in the human leukocyte antigen (HLA) system, encodes a part of the major histocompatibility complex (MHC) class II molecule, which plays a vital role in the immune response by presenting peptides to CD4+ T cells. Variations and polymorphisms in the HLA-DRB1 gene are associated with susceptibility to various autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and type 1 diabetes, making it a significant focus of research in immunology and genetics. The recombinant protein of HLA-DRB1 serves as a valuable tool for studying the structural and functional aspects of this molecule, understanding its interaction with different peptides, and elucidating the molecular mechanisms underlying immune responses. Moreover, the expression of recombinant HLA-DRB1 can facilitate the development of therapeutic strategies, including vaccine design and immunotherapies, by providing insights into how variations in this gene influence disease risk and progression. Through advanced techniques such as recombinant DNA technology and protein engineering, researchers aim to produce high-quality HLA-DRB1 proteins for detailed analysis, which can ultimately contribute to personalized medicine approaches in treating autoimmune conditions and improving transplant outcomes. Thus, the study of HLA-DRB1 recombinant proteins not only enhances our understanding of basic immunological processes but also holds promise for translational applications in clinical settings.
